Sensory neural hearing loss after concurrent cisplatin and radiation therapy for nasopharyngeal carcinoma

Radiother Oncol. 2004 Jul;72(1):79-82. doi: 10.1016/j.radonc.2004.02.009.

Abstract

Sensory neural hearing loss (SNHL) was evaluated in the patients who were treated with concurrent chemoradiation therapy for nasopharyngeal carcinoma. Ten from 48 ears showed persistent SNHL. Radiotherapy techniques, radiation dose to inner ear and post-treatment otitis media were significant predicting factors for SNHL.

MeSH terms

  • Adult
  • Carcinoma / drug therapy*
  • Carcinoma / radiotherapy*
  • Cisplatin / adverse effects*
  • Cisplatin / therapeutic use
  • Combined Modality Therapy
  • Female
  • Hearing Loss, Sensorineural / epidemiology*
  • Hearing Loss, Sensorineural / etiology*
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Nasopharyngeal Neoplasms / drug therapy*
  • Nasopharyngeal Neoplasms / radiotherapy*
  • Prospective Studies
  • Radiation Injuries / physiopathology*

Substances

  • Cisplatin